300142 沃森生物
已收盘 04-13 15:00:00
资讯
新帖
简况
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 04-10
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
A股收评：美伊停火引爆！沪指剑指4000点，贵金属、AI应用爆发
格隆汇 · 04-08
A股收评：美伊停火引爆！沪指剑指4000点，贵金属、AI应用爆发
沃森生物（300142）披露2026年第二次临时股东会决议公告，4月3日股价下跌2.68%
证券之星 · 04-03
沃森生物（300142）披露2026年第二次临时股东会决议公告，4月3日股价下跌2.68%
沃森生物资本腾挪背后：业绩下滑现金却被大幅消耗？少数股东“低买高卖”谁在套利
新浪证券 · 04-03
沃森生物资本腾挪背后：业绩下滑现金却被大幅消耗？少数股东“低买高卖”谁在套利
沃森生物：持续加强与全球健康组织和海外生物药企的交流与合作
证券之星 · 03-30
沃森生物：持续加强与全球健康组织和海外生物药企的交流与合作
股市必读：沃森生物年报 - 第四季度单季净利润同比增长112.52%
证券之星 · 03-30
股市必读：沃森生物年报 - 第四季度单季净利润同比增长112.52%
沃森生物(300142.SZ)发布2025年度业绩，归母净利润1.78亿元，增长25.03%
智通财经 · 03-27
沃森生物(300142.SZ)发布2025年度业绩，归母净利润1.78亿元，增长25.03%
沃森生物等来的不是招商局，而是一家北京地产商
蓝鲸财经 · 03-27
沃森生物等来的不是招商局，而是一家北京地产商
三月已有3起深交所上市公司控制权交易买方锁定60个月
文艺馥欣 · 03-26
三月已有3起深交所上市公司控制权交易买方锁定60个月
“落难”疫苗明星打折定增，沃森生物能否逆风翻盘？
微博财经-财道工作室 · 03-24
“落难”疫苗明星打折定增，沃森生物能否逆风翻盘？
沃森生物（300142）披露详式权益变动报告书，3月20日股价上涨0.97%
证券之星 · 03-20
沃森生物（300142）披露详式权益变动报告书，3月20日股价上涨0.97%
城头换旗，疫苗龙头沃森生物易主世纪金源
蓝鲸财经 · 03-20
城头换旗，疫苗龙头沃森生物易主世纪金源
闽商二代20亿元入主！沃森生物将迎来首位实控人，去年疫苗总收入降8%
澎湃新闻 · 03-20
闽商二代20亿元入主！沃森生物将迎来首位实控人，去年疫苗总收入降8%
控制权变更！300142，前“福建首富”将入主！明天复牌
e公司 · 03-18
控制权变更！300142，前“福建首富”将入主！明天复牌
沃森生物最新公告：控股股东将变更为腾云新沃明起复牌
证券之星 · 03-18
沃森生物最新公告：控股股东将变更为腾云新沃明起复牌
沃森生物拟非公开发行A股募资不超过20亿元，补充营运资金
美股速递 · 03-18
沃森生物拟非公开发行A股募资不超过20亿元，补充营运资金
沃森生物(300142.SZ)筹划公司控制权变更事项 3月17日起停牌
智通财经 · 03-16
沃森生物(300142.SZ)筹划公司控制权变更事项 3月17日起停牌
沃森生物公告：因潜在控股权变动，公司股票自3月17日起停牌
美股速递 · 03-16
沃森生物公告：因潜在控股权变动，公司股票自3月17日起停牌
沃森生物最新公告：子公司签署海外市场战略合作协议
证券之星 · 03-13
沃森生物最新公告：子公司签署海外市场战略合作协议
沃森生物：公司高管团队有明确的职责分工
证券之星 · 03-11
沃森生物：公司高管团队有明确的职责分工
加载更多
公司概况
公司名称：
云南沃森生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2010-11-12
主营业务：
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业，也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。
发行价格：
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.53,"timestamp":1776063816000,"preClose":12.56,"halted":0,"volume":30694915,"delay":0,"changeRate":-0.0024,"floatShares":1561000000,"shares":1599000000,"eps":0.1334,"marketStatus":"已收盘","change":-0.03,"latestTime":"04-13 15:00:00","open":12.42,"high":12.64,"low":12.41,"amount":384000000,"amplitude":0.0183,"askPrice":12.54,"askSize":23,"bidPrice":12.53,"bidSize":1134,"shortable":0,"etf":0,"ttmEps":0.1334,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776130200000},"marketStatusCode":5,"adr":0,"adjPreClose":12.56,"symbolType":"stock","openAndCloseTimeList":[[1776043800000,1776051000000],[1776056400000,1776063600000]],"highLimit":13.82,"lowLimit":11.3,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.33,"roa":"--","peRate":93.928036,"roe":"1.91%","epsLYR":0.1111,"committee":0.652774,"marketValue":20040000000,"turnoverRate":0.0197,"status":1,"floatMarketCap":19553000000},"requestUrl":"/m/hq/s/300142","defaultTab":"news","newsList":[{"id":"2626154347","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2626154347","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626154347?lang=zh_cn&edition=full","pubTime":"2026-04-10 09:03","pubTimestamp":1775782990,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司九价HPV疫苗进入大三期临床了吗？什么是大三期？从三期临床开始到疫苗上市都有哪些环节？贵司九价HPV疫苗目前处于哪个环节？沃森生物回复：尊敬的投资者，您好！公司九价HPV疫苗目前处于III期临床研究阶段，公司将按照国家对于注册临床试验的有关程序和要求推进相关工作。关于相关产品的后续进展情况请持续关注公司披露的信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000007760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","159646","BK0239","BK0070","BK0077","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625691560","title":"A股收评：美伊停火引爆！沪指剑指4000点，贵金属、AI应用爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2625691560","media":"格隆汇","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625691560?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:42","pubTimestamp":1775634144,"startTime":"0","endTime":"0","summary":"全市场成交额2.45万亿元，超5100股上涨","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2/101.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/101.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d4621a4347f62f73217129ec8b33f217","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4338263","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["399006","XAUUSD.FOREX","300142","510880","510300","159967","BK4585","BK4588","000001","000688.SH","GLD","512510","000905.SH","000607","512880","515890","300308","300418","000300.SH","399001"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2624668743","title":"沃森生物（300142）披露2026年第二次临时股东会决议公告，4月3日股价下跌2.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668743","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668743?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:10","pubTimestamp":1775225427,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，沃森生物报收于12.35元，较前一交易日下跌2.68%，最新总市值为197.52亿元。该股当日开盘12.62元，最高12.7元，最低12.29元，成交额达4.79亿元，换手率为2.48%。近日，云南沃森生物技术股份有限公司发布《2026年第二次临时股东会决议公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0239","BK0046","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652646","title":"沃森生物资本腾挪背后：业绩下滑现金却被大幅消耗？少数股东“低买高卖”谁在套利","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624652646?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:19","pubTimestamp":1775215140,"startTime":"0","endTime":"0","summary":"值得注意的是，少数股权在上述系列腾挪或成功上演了““低买高卖”式套利，即在标的产品即将上市前夕精准相对低价入股，随着业绩持续缩水又相对高价卖给上市公司。这一系列资本腾挪背后究竟有没有利益输送？ 近日，沃森生物发布2025年年报，业绩处在持续下滑“泥潭”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-03/doc-inhtfres0174173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK0070","BK0046","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390485","title":"沃森生物：持续加强与全球健康组织和海外生物药企的交流与合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623390485?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:45","pubTimestamp":1774860330,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月30日在投资者关系平台上答复投资者关心的问题。公司持续加强与全球健康组织和海外生物药企的交流与合作，采取多元化合作模式，深入推进产品在海外市场的注册和出口业务，并加快海外本地化产业项目的建设，不断拓展海外市场，为公司和股东创造价值。关于公司国际业务的开展情况请持续关注公司披露的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000022081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0077","BK0070","300142","159839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623350914","title":"股市必读：沃森生物年报 - 第四季度单季净利润同比增长112.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623350914","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623350914?lang=zh_cn&edition=full","pubTime":"2026-03-30 03:34","pubTimestamp":1774812852,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动截至2026年2月28日，公司股东户数为11.88万户，较2025年12月31日增加5798.0户，增幅5.13%。2025年第四季度单季度主营收入6.99亿元，同比增长2.84%；单季度归母净利润1429.86万元，同比增长112.52%；单季度扣非净利润2491.08万元，同比增长121.56%。公司公告汇总2025年年度报告摘要2025年公司实现营业收入24.18亿元，同比下降14.29%；归母净利润1.78亿元，同比增长25.03%；扣非净利润9545.09万元，同比下降11.94%。自主疫苗产品销售收入21.52亿元，占总收入89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000000725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622828568","title":"沃森生物(300142.SZ)发布2025年度业绩，归母净利润1.78亿元，增长25.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622828568","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622828568?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:37","pubTimestamp":1774607832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)发布2025年年度报告，该公司营业收入为24.18亿元，同比减少14.29%。归属于上市公司股东的净利润为1.78亿元，同比增长25.03%。归属于上市公司股东的扣除非经常性损益的净利润为9545.09万元，同比减少11.94%。基本每股收益为0.1111元。此外，拟向全体股东每10股派发现金红利1.25元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622681577","title":"沃森生物等来的不是招商局，而是一家北京地产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2622681577","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622681577?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:58","pubTimestamp":1774576734,"startTime":"0","endTime":"0","summary":"沃森生物日前披露，公司正在筹划定增，可能导致控制权发生变更。然而，沃森生物最终等来的，却是一家远在北京的民营地产商。深陷多重困境的沃森生物，此次定增，既是无奈之举，也是主动求生。此次入主沃森生物，是黄涛在大健康赛道落下的重要一子。本次发行完成后，腾云新沃将直接持有沃森生物11.51%股权，成为第一大股东。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774339767435771318","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","BK0046","BK0077","300142","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622869852","title":"三月已有3起深交所上市公司控制权交易买方锁定60个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2622869852","media":"文艺馥欣","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622869852?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:01","pubTimestamp":1774533660,"startTime":"0","endTime":"0","summary":"我们观察到3月已有3起深交所上市公司控制权交易，收购方自愿性承诺股份锁定60个月，并且在股权质押、资产注入安排等方面也有所收紧，呈现出沪深交易所要求趋同的现象，这一要求是否将持续以及所传递的信号值得高度关注。腾云新沃成为公司控股股东，黄涛将成为公司实际控制人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-26/doc-inhsiqkn0141820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0150","BK0028","BK0070","BK0160","BK0046","BK0004","300142","002569","BK0081","BK0251","BK0253","300385","BK0102","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095555","title":"“落难”疫苗明星打折定增，沃森生物能否逆风翻盘？","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095555","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095555?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:20","pubTimestamp":1774362000,"startTime":"0","endTime":"0","summary":"困局还是必然选择在资本市场中，定增折价并不罕见，但沃森生物此次超过20%的折价幅度，仍让不少投资者感到意外。与此同时，沃森生物在九价HPV疫苗、mRNA带状疱疹疫苗上的每年研发费用均保持在较高水平，进一步加剧了资金压力。从现金流来看，沃森生物的资金状况也不容乐观。此次定增后，黄涛通过腾云新沃及一致行动人持有14.46%的表决权，成为沃森生物绝对控股股东，而创始人李云春直接持股仅1.70%，持股比例极低。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-03-24/doc-inhscaeq1631327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300142","159646","BK0046","BK0070","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620488781","title":"沃森生物（300142）披露详式权益变动报告书，3月20日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620488781","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620488781?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:17","pubTimestamp":1773998231,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，沃森生物报收于12.51元，较前一交易日上涨0.97%，最新总市值为200.08亿元。近日，公司披露《详式权益变动报告书》。公告显示，北京腾云新沃生物科技合伙企业拟认购沃森生物向特定对象发行的207,983,751股股票，发行价格为9.63元/股，认购金额不超过200,288.35万元。本次发行完成后，腾云新沃将持有沃森生物11.51%的股份，并取得公司控制权，黄涛将成为实际控制人。本次权益变动尚需通过沃森生物股东会批准、深交所审核及证监会注册等程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000029783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0239","300142","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620678347","title":"城头换旗，疫苗龙头沃森生物易主世纪金源","url":"https://stock-news.laohu8.com/highlight/detail?id=2620678347","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620678347?lang=zh_cn&edition=full","pubTime":"2026-03-20 15:32","pubTimestamp":1773991974,"startTime":"0","endTime":"0","summary":"持续十六年股权分散、无实控人的治理格局正式落幕，民营资本巨头世纪金源通过定增入局，以低成本拿下控制权，开启疫苗产业与多元资本深度融合的新周期。在 A 股市场，世纪金源已形成三平台控股格局：2022 年入主皖通科技，布局智慧交通；2025 年拿下安奈儿，切入大消费；此次控股沃森生物，正式挺进高端疫苗制造。夜色降临，沃森产业园的灯光与生产线运转声交织，见证这家疫苗龙头的历史转折。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773934239362799337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300142","BK0046","BK0070","BK0077","BK0239","159645"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620204382","title":"闽商二代20亿元入主！沃森生物将迎来首位实控人，去年疫苗总收入降8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620204382","media":"澎湃新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620204382?lang=zh_cn&edition=full","pubTime":"2026-03-20 12:15","pubTimestamp":1773980100,"startTime":"0","endTime":"0","summary":"上市16年，国内民营疫苗龙头企业沃森生物迎来首位实际控制人。此次黄涛成为沃森生物的实际控制人，也意味着世纪金源开始涉足疫苗业务。对于2025年业绩的变化，沃森生物称，报告期内，国内外疫苗市场总体仍处于下行周期，公司疫苗产品总收入较上年同期下降约8%。截至3月20日午盘，沃森生物涨0.32%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-03-20/doc-inhrrera0842698.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-20/doc-inhrrera0842698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300142","159646","BK0070","BK0077","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620620256","title":"控制权变更！300142，前“福建首富”将入主！明天复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620620256","media":"e公司","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620620256?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:49","pubTimestamp":1773838140,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 沃森生物股票3月19日开市起复牌。公司首任实控人将要揭晓。 上市近16年，沃森生物将迎来首任实控人，背后有意斥资近20亿元入主上市公司的资本方，来自知名闽商黄如论、黄涛家族。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-03-18/doc-inhrmpqp9198529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","300142","BK0070","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620323211","title":"沃森生物最新公告：控股股东将变更为腾云新沃明起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620323211","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620323211?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:41","pubTimestamp":1773830483,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司正筹划向腾云新沃发行股票，发行价格9.63元/股，募集资金总额不超过20.03亿元，扣除发行费用后全部用于补充流动资金。发行后，腾云新沃持股11.51%，与其一致行动人合计持股14.46%，公司控股股东将变更为腾云新沃，实际控制人变更为黄涛。公司股票自3月19日开市起复牌。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800033540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","300142","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104710629","title":"沃森生物拟非公开发行A股募资不超过20亿元，补充营运资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1104710629","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104710629?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:38","pubTimestamp":1773830305,"startTime":"0","endTime":"0","summary":"沃森生物今日宣布，公司计划通过非公开发行A股股票的方式，募集资金总额不超过人民币20亿元，所募资金将主要用于补充公司营运资金及优化财务结构。此次非公开发行对象为不超过35名特定投资者，发行价格不低于定价基准日前20个交易日公司股票交易均价的80%。截至今日收盘，沃森生物股价报收XX元，当日涨跌幅XX%。本次非公开发行方案尚需公司股东大会审议通过及深交所审核、中国证监会注册后方可实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK0046","BK0239","300142","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619157455","title":"沃森生物(300142.SZ)筹划公司控制权变更事项 3月17日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157455","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619157455?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:00","pubTimestamp":1773651637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)发布公告，公司正在筹划向特定对象发行A股股票，该事项可能会导致公司控制权发生变更。目前，各方主体正在就具体方案、协议等相关事项进行论证和磋商，具体情况以各方最终签署的相关协议为准。经公司向深圳证券交易所申请，公司股票自2026年3月17日(星期二)开市起停牌，预计停牌时间不超过2个交易日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0046","BK0239","300142","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148460144","title":"沃森生物公告：因潜在控股权变动，公司股票自3月17日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148460144","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148460144?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:52","pubTimestamp":1773651132,"startTime":"0","endTime":"0","summary":"沃森生物（300142）发布公告称，因公司可能发生控股权变更的重大事项，为维护投资者利益并确保信息公平披露，公司股票自2024年3月17日开市起停牌。待相关事项确定后，公司将及时发布进展公告并申请复牌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300142","BK0077","BK0070","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619686199","title":"沃森生物最新公告：子公司签署海外市场战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2619686199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619686199?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:01","pubTimestamp":1773399677,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司全资子公司香港沃森近日与江苏中慧元通生物科技股份有限公司（简称“中慧元通”）签署了《海外市场战略合作协议》，就双方进行海外市场战略合作达成一致。双方同意，中慧元通及其附属公司指定香港沃森（或香港沃森指定的关联方）为疫苗产品（指由中慧元通生产的三价流感病毒亚单位疫苗）在区域（指除菲律宾、澳门以外的其他地域，包括公立和私立市场）内的国际业务开发排他的合作伙伴，负责疫苗产品与区域内的注册（含可能需要的当地临床试验）、推广及销售。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300033450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0070","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618980129","title":"沃森生物：公司高管团队有明确的职责分工","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980129?lang=zh_cn&edition=full","pubTime":"2026-03-11 08:27","pubTimestamp":1773188823,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2026年董事会换届已完成，新当选非独立董事具备国药集团背景，且组织架构已完成精简优化。请问换届后高管团队的核心分工是否明确，国药体系的产业资源、渠道资源已落地哪些具体合作？本次组织架构调整，公司高管团队有明确的职责分工。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100007251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300142","BK0070","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776094395109,"stockEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.0537},{"period":"3month","weight":0.0363},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.148},{"period":"ytd","weight":0.1542}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118767人(较上一季度增加5.13%)","perCapita":"13139股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业，也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}